Related Experiment Video
Updated: Jun 3, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Cardiac resynchronization therapy: prospect for long-lasting heart failure remission
1Department of Internal Medicine (Cardiology, and Clinical Cardiac Electrophysiology), The University of Texas Southwestern Medical Center, Dallas, TX, USA. shining.sun@gmail.com
Summary
Cardiac resynchronization therapy (CRT) offers a vital treatment for heart failure (HF) patients with systolic dysfunction. This review covers CRT
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Heart failure (HF) is a significant and growing healthcare challenge in the US, particularly with an aging population.
- Advances in pharmacologic and device-based therapies have improved HF management.
- Cardiac resynchronization therapy (CRT) has emerged as a key therapeutic option for HF with systolic dysfunction.
Purpose of the Study:
- To review the physiologic basis and clinical evidence supporting CRT.
- To outline current indications for CRT use in heart failure patients.
- To explore ongoing research questions and future directions for CRT.
Main Methods:
- Review of existing literature on CRT.
- Analysis of clinical trial data supporting CRT efficacy.
- Discussion of current and potential future indications for CRT.
Main Results:
- CRT is an important therapeutic option for heart failure due to systolic dysfunction.
- Clinical trials demonstrate the efficacy of CRT.
- Current indications for CRT are established, with ongoing research into predictors of response.
Conclusions:
- CRT has proven efficacy in treating specific heart failure populations.
- Further research is needed to optimize CRT use and expand its indications.
- Future research may identify predictors of response and broaden CRT's applicability.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...